Hafezi Nasim, Alizadeh-Navaei Reza, Golpour Monireh, Zafari Parisa, Ajami Abolghasem
Department of Immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
Molecular and Cell Biology Research Center, Student Research Committee, Mazandaran University of Medical Sciences, Sari, Iran.
Caspian J Intern Med. 2022 Winter;13(1):1-9. doi: 10.22088/cjim.13.1.1.
Frizzled receptors (FZD) play a pivotal role in the initiation and progression of a wide array of cancers. Dysregulated expression of FZD receptors is correlated with higher metastasis and invasive potential, as well as short survival in many malignancies. In this meta-analysis, we aimed to verify the prognostic value of FZD receptor expression on patients' survival with different types of gastrointestinal (GI) cancers, including gastric, colorectal, and esophageal cancers.
A systematic search was performed using PubMed, Scopus, and Web of Science from 2000 to November 2020. Fourteen studies, including 2997 patients met our inclusion criteria, in which nine articles were considered FZD7 while the rest were about other FZD members. The fixed-effect model was used to estimate the pooled hazard ratio (HR) and the 5-year overall survival (OS) rate. We used the Newcastle-Ottawa scale of cohort articles to determine the quality of included studies.
The results showed that high expression of FZD receptors is associated with the poor survival in patients with GI cancers (HR= 1.83, 95% CI: 1.5-2.17). Moreover, multivariate analysis indicated that FZD receptors could be considered as an independent prognostic factor (HR = 1.76, 95% CI: 1.37-2.16).
According to our results, overexpression of FZD receptors predicts a poor prognosis in patients with GI cancers and could be used as a useful therapeutic target.
卷曲受体（FZD）在多种癌症的发生和发展中起关键作用。FZD受体的表达失调与更高的转移和侵袭潜能相关，并且在许多恶性肿瘤中与较短的生存期相关。在这项荟萃分析中，我们旨在验证FZD受体表达对不同类型胃肠道（GI）癌症患者生存的预后价值，包括胃癌、结直肠癌和食管癌。
使用PubMed、Scopus和Web of Science对2000年至2020年11月进行系统检索。14项研究，包括2997名患者符合我们的纳入标准，其中9篇文章涉及FZD7，其余文章涉及其他FZD成员。采用固定效应模型估计合并风险比（HR）和5年总生存率（OS）。我们使用队列文章的纽卡斯尔-渥太华量表来确定纳入研究的质量。
结果表明，FZD受体高表达与GI癌症患者的不良生存相关（HR = 1.83，95%CI：1.5 - 2.17）。此外，多变量分析表明FZD受体可被视为独立的预后因素（HR = 1.76，95%CI：1.37 - 2.16）。
根据我们的结果，FZD受体过表达预示着GI癌症患者预后不良，可作为一个有用的治疗靶点。
